title: Margin width should not still enforce a systematic surgical re-excision in the conservative treatment of early breast infiltrative ductal carcinoma.
abstract: BACKGROUND
  In cases where breast conservative surgery was performed for infiltrative ductal carcinoma (IDC), margin status is an independent prognostic factor for local ipsilateral relapse (LIR). There is no validated definition of a clear margin. We investigated factors associated with residual disease on re-excision specimen and the impact of margin status on the risk of LIR.
  
  
  METHODS
  From January 1992 to December 2002, 454 patients were retrospectively included. Patients had undergone conservative surgery and radiotherapy for IDC. Two groups were defined: group 1, involved or close margin (<3 mm) and a re-excision; and group 2, involved or close margin without re-excision. The risk factors for residual disease in the re-excision specimen were analyzed in group 1, and the rate of 5-year LIR was analyzed in both groups.
  
  
  RESULTS
  Among patients who experienced a surgical re-excision for involved or close margin, 21% (55 of 206) had residual tumor. The multivariate analysis showed that only a margin involved with intraductal carcinoma remained predictive for residual disease. According to the multivariate analysis, only hormone therapy (p < 10(-6)), diffuse involved margins (p = 0.003), and margins involved with intraductal component (p < 10(-6)) were predictive of LIR. Re-excision for a margin involved with intraductal carcinoma significantly improved local relapse-free survival (p < 0.001).
  
  
  CONCLUSIONS
  In cases of IDC, re-excision for a close margin or a focally involved margin had no impact on local relapse-free survival. The decision to perform a surgical re-excision for an involved margin should not be systematic but should take multiple risk factors into consideration, such as patient age or margin diffuse involvement.
authors.affiliation: Department of Surgical Oncology, Centre Gauducheau, Institut de Cancerologie de l'Ouest, Saint Herblain, France, isabelle.jaffre@ico.unicancer.fr.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Jaffré
authors.forename: Loic
authors.initials: L
authors.lastname: Campion
authors.forename: Magali
authors.initials: M
authors.lastname: Dejode
authors.forename: Virginie
authors.initials: V
authors.lastname: Bordes
authors.forename: Christine
authors.initials: C
authors.lastname: Sagan
authors.forename: Delphine
authors.initials: D
authors.lastname: Loussouarn
authors.forename: François
authors.initials: F
authors.lastname: Dravet
authors.forename: Nicole
authors.initials: N
authors.lastname: Andrieux
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Classe
mesh_terms: D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate